The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into clinical care to better support mBC patients. The main question the study aims to answer is: is the patient navigation program feasible and acceptable for mBC patients?
Participants will receive patient navigation sessions over about 6 weeks. Participants will also complete study assessments via electronic survey at baseline and at about 3 and 6 weeks after enrollment, with the last assessment occurring after completion of the patient navigation program sessions. Participants will also complete a post-program exit interview.
female (sex assigned at birth);
≥18 years of age at enrollment;
diagnosed with HER2+ metastatic breast cancer (mBC);
receiving treatment with tucatinib combined with capecitabine and trastuzumab;
visual or hearing impairment;
severe cognitive impairment;
severe mental illness interfering with ability to participate
Duke University
Lead sponsor
Pfizer
Collaborator